Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Bhowmick, Sudipta ^a   Ali, Nahid ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; DODECYL SULFATE SODIUM; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; LIPOSOME; PARASITE ANTIGEN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; ANTIGEN; CYTOKINE; IMMUNOGLOBULIN G; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; DRUG PURIFICATION; ELUTION; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; LEISHMANIA DONOVANI; LEISHMANIASIS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; ANIMAL; CELL PROLIFERATION; CHEMISTRY; IMMUNOLOGY; METABOLISM; PROTEIN TERTIARY STRUCTURE; VISCERAL LEISHMANIASIS;

LEISHMANIA DONOVANI; MUS; NASO HEXACANTHUS;

ANIMALS; ANTIGENS; CELL PROLIFERATION; CYTOKINES; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-4; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIPOSOMES; MICE; MICE, INBRED BALB C; PROTEIN STRUCTURE, TERTIARY; VACCINES;

EID: 67149120531     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005820     Document Type: Article

References (58)

1. Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27: 305-318.
2. Ivens AC, Peacock CS, Worthey EA, et al. (2005) The genome of the kinetoplastid parasite, Leishmania major. Science 309: 436-442.
3. Ashton PD, Curwen RS, Wilson RA (2001) Linking proteome and genome: how to identify parasite proteins. Trends Parasitol 17: 198-202.
4. Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S (2005) Kinetoplastid membrane protein- 11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and-resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174: 7160-7171.
5. Stager S, Smith DF, Kaye PM (2000) Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 165: 7064-7071.
6. Ghosh A, Zhang WW, Matlashewski G (2001) Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20: 59-66.
7. Tewary P, Jain M, Sahani MH, Saxena S, Madhubala R (2005) A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis. J Infect Dis 91: 2130-2137.
8. Rafati S, Zahedifard F, Nazgouee F (2006) Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24: 2169-2175.
9. Bhowmick S, Ali N (2008) Recent developments in leishmaniasis vaccine delivery systems. Expert Opin Drug Deliv 5: 789-803.
10. Melby PC, Yang J, Zhao W, Perez LE, Cheng J (2001) Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 69: 4719-4725.
11. Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, et al. (2005) Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 73: 812-819.
12. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG (2007) Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect Immun 75: 4648-4654.
13. McMahon-Pratt D, Alexander J (2004) Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? Immunol Rev 201: 206-224.
14. Engwerda CR, Murphy ML, Cotterell SE, Smelt SC, Kaye PM (1998) Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur J Immunol 28: 669-680.
15. Murray HW, Hariprashad J, Coffman RL (1997) Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. J Exp Med 185: 867-874.
16. Kaye PM, Curry AJ, Blackwell JM (1991) Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol 146: 2763-2770.
17. Miralles GD, Stoeckle MY, McDermott DF, Finkelman FD, Murray HW (1994) Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun 62: 1058-1063.
18. Satoskar A, Bluethmann H, Alexander J (1995) Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect Immun 63: 4894-4899.
19. Stober CB, Lange UG, Roberts MT, Alcami A, Blackwell JM (2005) IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J Immunol 175: 2517-2524.
20. Afrin F, Ali N (1997) Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect Immun 65: 2371-2377.
21. Ravindran R, Anam K, Bairagi BC, Saha B, Pramanik N, et al. (2004) Characterization of immunoglobulin G and its subclass response to Indian kalaazar infection before and after chemotherapy. Infect Immun 72: 863-870.
22. Bhowmick S, Ravindran R, Ali N (2008) gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect Immun 76: 1003-1015.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with Folin phenol reagent. J Biol Chem 193: 265-276.
24. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
25. Afrin F, Rajesh R, Anam K, Gopinath M, Pal S, et al. (2002) Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infect Immun 70: 6697-6706.
26. Stauber LA, Franchino EM, Grun J (1958) An 8-day method for screening compounds against Leishmania donovani in the golden hamster. J Protozool 5: 269-273.
27. Mazumdar T, Anam K, Ali N (2004) A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 22: 1162-1171.
28. Afrin F, Ali N (1998) Isotype profiles of Leishmania donovani-infected BALB/c mice: preferential stimulation of IgG2a/b by liposome-associated promastigote antigens. J Parasitol 84: 743-748.
29. Bhowmick S, Ravindran R, Ali N (2007) Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response. Vaccine 25: 6544-6556.
30. Mukhopadhyay S, Bhattacharyya S, Majhi R, De T, Naskar K, et al. (2000) Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis. Clin Diagn Lab Immunol 7: 233-240.
31. Coffman RL, Lebman DA, Rothman P (1993) Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol 54: 229-270.
32. Rosenkrands I, Weldingh K, Ravn P, Brandt L, Højrup P, et al. (1999) Differential T-cell recognition of native and recombinant Mycobacterium tuberculosis GroES. Infect Immun 67: 5552-5558.
33. Kemp M, Kurtzhals JA, Kharazmi A, Theander TG (1993) Interferon-gamma and interleukin-4 in human Leishmania donovani infections. Immunol Cell Biol 71: 583-587.
34. Campos-Neto A, Soong L, Cordova JL, Sant'Angelo D, Skeiky YA, et al. (1995) Cloning and expression of a Leishmania donovani gene instructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages. J Exp Med 182: 1423-1433.
35. Coler RN, Reed SG (2005) Second-generation vaccines against leishmaniasis. Trends Parasitol 21: 244-249.
36. Martins DR, Jeronimo SM, Donelson JE, Wilson ME (2006) Leishmania chagasi T-cell antigens identified through a double library screen. Infect Immun 74: 6940-6948.
37. Bhatia A, Daifalla NS, Jen S, Badaro R, Reed SG, et al. (1999) Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi. Mol Biochem Parasitol 102: 249-261.
38. Ghedin E, Zhang WW, Charest H, Sundar S, Kenney RT, et al. (1997) Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis. Clin Diagn Lab Immunol 4: 530-535.
39. Scott P, Artis D, Uzonna J, Zaph C (2004) The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Immunol Rev 201: 318-338.
40. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK (1993) Recombinant interleukin-12 cures mice infected with Leishmania major. J Exp Med 177: 1505-1509.
41. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, et al. (1994) The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263: 235-237.
42. Kamogawa Y, Minasi LA, Carding SR, Bottomly K, Flavell RA (1993) The relationship of IL-4- and IFN gamma-producing T cells studied by lineage ablation of IL-4-producing cells. Cell 75: 985-995.
43. Platzer C, Richter G, Uberla K, Muller W, Blocker H, et al. (1992) Analysis of cytokine mRNA levels in interleukin-4-transgenic mice by quantitative polymerase chain reaction. Eur J Immunol 22: 1179-1184.
44. D'Andrea A, Ma X, Aste-Amezaga M, Paganin C, Trinchieri G (1995) Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor alpha production. J Exp Med 181: 537-546.
45. Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F (2000) Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 30: 2935-2943.
46. Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, et al. (2007) Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. Vaccine 25: 4159-4169.
47. Målen H, Berven FS, Søfteland T, Arntzen MØ, D'Santos CS, et al. (2008) Membrane and membrane-associated proteins in Triton X-114 extracts of Mycobacterium bovis BCG identified using a combination of gel-based and gel-free fractionation strategies. Proteomics 8: 1859-1870.
48. Connolly JP, Comerci D, Alefantis TG, Walz A, Quan M, et al. (2006) Proteomic analysis of Brucella abortus cell envelope and identification of immunogenic candidate proteins for vaccine development. Proteomics 6: 3767-3780.
49. Gupta SK, Sisodia BS, Sinha S, Hajela K, Naik S, et al. (2007) Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes. Proteomics 7: 816-823.
50. Jones A, Faldas A, Foucher A, Hunt E, Tait A, et al. (2006) Visualisation and analysis of proteomic data from the procyclic form of Trypanosoma brucei. Proteomics 6: 259-267.
51. Tabatabai LB, Zehr ES (2004) Identification of five outer membrane-associated proteins among cross-protective factor proteins of Pasteurella multocida. Infect Immun 72: 1195-8.
52. Probst P, Stromberg E, Ghalib HW, Mozel M, Badaro R, et al. (2001) Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning. J Immunol 166: 498-505.
53. Theinert SM, Basu R, Forgber M, Roy S, Sundar S, et al. (2005) Identification of new antigens in visceral leishmaniasis by expression cloning and immunoblotting with sera of kala-azar patients from Bihar, India. Infect Immun 73: 7018-7021.
54. Rosenzweig D, Smith D, Myler PJ, Olafson RW, Zilberstein D (2008) Post-translational modification of cellular proteins during Leishmania donovani differentiation. Proteomics 8: 1843-1850.
55. Campbell K, Diao H, Ji J, Soong L (2003) DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous leishmaniasis. Infect Immun 71: 6270-6278.
56. Carrillo E, Crusat M, Nieto J, Chicharro C, Thomas Mdel C, et al. (2008) Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis. Vaccine 26: 1902-1911.
57. Qazi KR, Oehlmann W, Singh M, López MC, Fernández C (2007) Microbial heat shock protein 70 stimulatory properties have different TLR requirements. Vaccine 25: 1096-1103.
58. Skeiky YAW, Benson DR, Guderian JA, Whittle JA, Bacelar O, et al. (1995) Immune responses of leishmaniasis patients to heat shoch proteins of Leishmania species and human. Infect Immun 63: 4105-4114.